Abstract Body

Primary HPV Screening (PHS) utilizes an oncogenic human papillomavirus (oncHPV) assay as the initial cervical cancer screening test (instead of a Pap test). Recent US guidelines support PHS in women in the general population (30-65 years of age), and suggest oncHPV- women should be retested in 5 years. For oncHPV+ women, reflex HPV genotyping is recommended and possibly an additional test (e.g., Pap test) in order to determine appropriate follow-up or triage to colposcopy. However, the current study is, to our knowledge, the first to assess PHS in WLWH. Cervical cancer screening strategies for WLWH need improvement as these women have elevated risk of cervical cancer relative to the general population, but current strategies result in a high rate of colposcopy that does not reflect clinically relevant cervical disease.

The study enrolled 865 WLWH comprised of 323 new enrollees in the Women’s Interagency HIV Study (WIHS) and 542 WLWH enrolled through colposcopy clinics affiliated with WIHS. Newly enrolled WIHS women represented WLWH undergoing routine screening. Colposcopy patients represented WLWH who had a recent abnormal screening test (e.g., ASC-US+). WIHS participants underwent routine screening using liquid-based Pap tests (ThinPrep) and were tested for oncHPV by the FDA-approved Cobas test. WIHS enrollees with a positive oncHPV or ASC-US+ received colposcopy, as did 15% of women with negative oncHPV and Pap results. Like WIHS enrollees, the WLWH enrolled at colposcopy had oncHPV and Pap tests. All Pap/histology was centrally reviewed by two expert pathologists.

Mean age was 47 years for both WIHS enrollees and colposcopy patients, and most were Hispanic or non-Hispanic African American. Median (IQR) CD4 count was 560 (342-843) and 631 (362-849), respectively, with 97% and 83% reporting cART use. There was a total of 70 CIN2+ of which 23 were CIN3+ (precancer). The Table shows sensitivity, specificity, and positive predictive value (PPV) to detect CIN3+, as well as the % of WLWH who would be triaged to colposcopy following several strategies. Results for PHS, as estimated by oncHPV with reflex Pap, had the highest PPV and lowest colposcopy rate; Co-Testing had moderately higher sensitivity and colposcopy triage rates.

The results show that PHS with reflex Pap testing is a potentially useful cervical cancer screening strategy in WLWH, but may sacrifice a moderate level of sensitivity for a moderate reduction in the rate of triage to colposcopy.